AUTHOR INDEX

Abdul-Hussain, M.N., 167
Allen, S.J., 117
Ang, L.-C., 189
Artigas, A., 138
Axler, O., 109

Baggstrom, E., 117
Beale, R., 180
Bernard, G.R., 9, 77
Bernardi, L., 65
Bittner, H.B., 43
Blanch, L., 138
Blank, G.S., 189
Brown, S.D., 2

Calciatti, A., 65
Carmichael, L.C., 9
Chen, E.P., 43
Chen, L., 57, 206
Clanton, T.L., 129
Clark, C., 2
Cohen, R.I., 27, 206
Cujec, B., 189

Dall'ava-Santucci, J., 109
de la Bellacasa, J.P., 122
Donovan, D., 117
Dorinsky, P.M., 9
Dupont, W.D., 9

El-Dwairi, Q., 167
El-Ebiary, M., 122

Fernandez, E., 197
Fernandez, R., 138
Fogarty, S., 176
Fox, J.A., 189

Gadek, J.E., 129
Gayowski, T.J.P., 51
Geiger, M.I.B., 43
Genovese, J., 27
Gonzalez, J., 122
Guice, K.S., 43
Gutierrez, G., 1, 2, 197

Hernández, C., 122
Higgins, S.B., 9
Hirschl, R.B., 37
Huberfeld, S., 27
Hurst, T., 189
Hussain, S.N.A., 19, 167

Johnson, D., 189

Kendall, S.W.H., 43
Kiiski, R., 197
Koch, S.M., 117, 176
Kruse, J.A., 144

Lee, D.H., 197
Lichtwarck-Aschoff, M., 180
Lodato, R.F., 151

Magder, S., 155
Mayers, I., 189
Mehlhorn, U., 117, 176
Mehta, N., 51
Montón, C., 122

Op't Holt, T.B., 129
Oud, L., 144
Overbeck, M.C., 37

Pantaleo, P., 65
Parmley, L., 176
Perlini, S., 65
Pfeiffer, U.J., 180
Phang, P.T., 109
Pinsky, M.R., 65, 95
Pranikoff, T., 37

Rao, P.S., 57
Richardson, J.S., 189
Russell, J.A., 109

Saxena, A., 189
Scharf, S.M., 27, 57, 206
Schlichtig, R., 51
Signorino, C., 176
Slamowitz, D., 57
Solda, P.L., 65
Steinberg, H.N., 27
Swindell, B., 9

Thompson, C.R., 109
Thomson, D., 189
Torres, A., 122
Tousignant, C., 109

Vanelli, G., 155
Van Trigt, P., 43

Walley, K.R., 109
Ward, M.E., 19
Waugh, J.B., 129
Wheeler, A.P., 9, 77

SUBJECT INDEX

Acute renal failure (ARF), isolated organ-system dysfunction and, 102
Added dead space, effect on inhaled nitric oxide, 138-143
α-Adrenoreceptor stimulation, of oxygen delivery-consumption, 19-25
Adult respiratory distress syndrome (ARDS)
  diagnosis, 9-18
  high-dose furosemide in, 129-137
  isolated organ-system dysfunction and, 102
  pulmonary lactate release in, 2-7
  therapy, 9-18
Animal models. *See also specific animal models*
  large, partial liquid ventilation in, 37-42
Anti-CD18 antibody, post CABG cardiac function and, 189-195
Anticytokine antibodies, for human sepsis, 88-90
Aortic occlusion, partial, 69-70
ARDS. *See* Adult respiratory distress syndrome (ARDS)
ARF (acute renal failure), isolated organ-system dysfunction and, 102

Blood pressure
  central venous, as indicator of cardiac preload, 180-188
  in sepsis, NOS inhibition and, 155-165
Blood volume, in sepsis, NOS inhibition and, 155-165
Brain death, nitric oxide role in, 43-49

CABG (coronary artery bypass), anti-CD18 antibody effects on post-op function, 189-195
Calcitonin, in acute trauma, 117-121
Calcium-regulatory hormones, in acute trauma, 117-121
Cardiac output
  CPAP effects on, 57-63
  measurement methods, comparison of, 109-116
  in sepsis, circuit factors in, 155-165
Cardiac preload, indicators of, 180-188

Cardiovascular derangement, in septic shock, 151-154
Centoxin, for human sepsis, 88
Central venous pressure, as indicator of cardiac preload, 180-188
Cerebral perfusion pressure (CPP), passive range of motion effects on, 176-179
Continuous positive airway pressure (CPAP), effects on cardiac output and plasma norepinephrine, 57-63
Coronary artery bypass (CABG), anti-CD18 antibody effects on post-op function, 189-195
CPP (cerebral perfusion pressure), passive range of motion effects on, 176-179
Cytokine paradigm, of sepsis, 98-99

Diaphragm, α-adrenoreceptor stimulation of oxygen delivery-consumption in, 19-25
Diastole, ventricular interdependence in, 72
Dogs
  brain death, nitric oxide role in, 43-49
  endotoxemic, NOS inhibition and fluid resuscitation effects on, 27-36
  myocardial blood flow and left ventricular function, L-NAME effects on, 206-212
  post CABG cardiac function, anti-CD18 antibody effect on, 189-195

Endotoxemia
  exhaled nitric oxide *vs.* serum levels in, 167-173
  NOS inhibition and fluid resuscitation effects on, 27-36
  vascular tone changes in, 155-165
Endotoxin antibodies, 86-88

Fick method, *vs.* other cardiac output measurement methods, 109-116
Fluid resuscitation, effect on myocardium in endotoxemia, 27-36
Furosemide, high-dose, in acute lung injury, 129-137

Gas exchange, in large animal model with partial liquid ventilation, 37-42
Gastric pH, intramucosal
  saline-filled balloon tonometry of, reproducibility of, 144-150
  ventilatory-associated pneumonia and, 122-128
  vs. tissue-arterial P_{CO_2} difference, for gastric oxygenation, 51-55

HA1A, for human sepsis, 88
Heart rate, in neurosurgical patients, passive range of motion effects on, 176-179
Hemodynamics
  after brain death, 43-49
  in sepsis, NOS inhibition and, 155-165
Hypercalcitoninemia, in acute trauma, 117-121

ICP (intracranial pressure), in neurosurgical patients, passive range of motion effects on, 176-179
Inspiratory-to-expiratory ratio, effect on inhaled nitric oxide, 138-143
Interior vena cava occlusion, 69
Intracranial pressure (ICP), in neurosurgical patients, passive range of motion effects on, 176-179
Intrathoracic blood volume, as indicator of cardiac preload, 180-188
Ischemia, tissue-arterial P_{CO_2} difference *vs.* pHi, 51-55

Lactate, pulmonary release in ARDS and sepsis, 2-7
Left ventricle
  after brain death, 46
  function, L-NAME effect on, 206-212
  pressure-volume relationships, 65-76

Mean arterial pressure (MAP), in neurosurgical patients, passive range of motion effects on, 176-179
Mean circulatory filling pressure (MCFP), in sepsis, 155-165
MODS. *See* Multiple-organ dysfunction syndrome (MODS)
Monoclonal antibodies
  antigen selection for, 79-80
  biology, 77-79
  production techniques, 81
  for sepsis, 86-90
  therapeutic uses, 77
  vs. polyclonal antibodies, 81-86
Multiple-organ dysfunction syndrome (MODS), 95-96
  conventional therapies as catalysts for, 101-104
  molecular therapies, failure of, 99-101
  organ-specific supportive therapies for, 104-105
Muscle fatigue, reversal by intravenous potassium chloride, 197-205
Myocardium
  blood flow, L-NAME effect on, 206-212
  in endotoxemia, NOS inhibition and fluid resuscitation effects on, 27-36

L-NAME
  hemodynamics in endotoxemia and, 155-165
  myocardial blood flow and left ventricular function effects of, 206-212
  in septic shock, 152-153
Nitric oxide (NO)
  cardiovascular derangement in septic shock and, 151-154
  exhaled *vs.* serum, in endotoxemia, 167-173
  inhaled, ventilatory factors in continuous-flow administration, 138-143
  role in brain death, 43-49
Nitric oxide synthase inhibition
  effect on myocardium in endotoxemia, 27-36
  left ventricular function and, 206-212
  myocardial blood flow and, 206-212
L-NMMA, in septic shock, 153
Norepinephrine, CPAP effects on, 57-63

Oxygenation
  in adult respiratory distress syndrome, 11
  diaphragmatic delivery-consumption relationship, stimulation of, 19-25
  gastric, comparison of measurement methods for, 51-55
Oxygen therapy, in adult respiratory distress syndrome, 11, 12
Oxygen toxicity, in adult respiratory distress syndrome, 11

Parathyroid hormone, in acute trauma, 117-121
Partial liquid ventilation, in large animal model, 37-42
Passive range of motion, effect on ICP and CPP in neurosurgical patients, 176-179
PEEP (positive end-expiratory pressure), for ARDS, 12
Pigs
  CPAP effects on cardiac output and plasma norepinephrine, 57-63
  high cardiac output of sepsis, circuit factors in, 155-166
Pneumonia, ventilatory-associated, intramucosal gastric pH and, 122-128
Polyclonal antibodies
  antigen selection for, 79-80
  biology, 77-79
  production techniques, 80-81
  for sepsis, 86-90
  therapeutic uses, 77
  vs. monoclonal antibodies, 81-86
Positive end-expiratory pressure (PEEP), for ARDS, 12
Potassium chloride, for reversal of muscle fatigue in rabbits, 197-204
Pulmonary artery catheters, in adult respiratory distress syndrome, 12
Pulmonary artery occlusion
  partial, 70-71
  pressure, as indicator of cardiac preload, 180-188

Rabbits
  reversal of muscle fatigue in, 197-204
  ventricular pressure-volume loops in, 65-76
Respiratory rate, passive range of motion effects on, 176-179
Right ventricle
  end-diastolic volume, as indicator of cardiac preload, 180-188
Right ventricle (*Continued*)
  function, after brain death, 46
  pressure-volume relationships, 65-76

Sepsis
  antibody therapy for, 77-94
  cytokine paradigm of, 98-99
  high cardiac output, circuit factors in, 155-165
  pulmonary lactate release in, 2-7
  therapy for, 86-90
Septic shock, cardiovascular derangement in, 151-154
Sheep, partial liquid ventilation in, 37-42
Systemic inflammatory response syndrome (SIRS), 95-96
  inflammatory process in, 96-98
  molecular therapies, failure of, 99-101
  organ-specific supportive therapies for, 104-105
Systole, ventricular interdependence in, 72-73

Thermodilution method, *vs.* other cardiac output measurement methods, 109-116
Tidal volume, effect on inhaled nitric oxide, 138-143
Tissue-arterial Pco_2 difference, in ischemia, 51-55
Tonometry, saline-filled balloon, reproducibility of intramucosal gastric pH determination, 144-150
Transesophageal echocardiography, for cardiac output *vs.* other methods, 109-116

Ventilation
  for adult respiratory distress syndrome, 11
  partial liquid, in large animal model, 37-42
Ventilator settings, effect on inhaled nitric oxide, 138-143
Ventilatory-associated pneumonia, intramucosal gastric pH and, 122-128
Vitamin D analogs, in acute trauma, 117-121

XOMEN E5, for human sepsis, 86-88